#1 Clinical Trials Search in Europe

Tolinapant Lactate

This article discusses the ongoing clinical trials investigating the use of Tolinapant Lactate, also known as ASTX660, in treating various advanced solid tumors and lymphomas. The trials aim to assess the safety, efficacy, and optimal dosing of this novel drug in patients with relapsed or refractory cancers, including peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and head and neck squamous cell carcinoma.

Table of Contents

What is Tolinapant?

Tolinapant, also known as ASTX660 or AT29660, is an investigational drug being studied for the treatment of various advanced cancers and lymphomas[1][2]. It is a new type of medication that belongs to a class of drugs called IAP (inhibitor of apoptosis protein) inhibitors. Tolinapant is currently in clinical trials to evaluate its safety and effectiveness in treating patients with certain types of cancer that have not responded well to other treatments or have come back after previous treatments.

How Does Tolinapant Work?

Tolinapant works by targeting and inhibiting proteins called IAPs (inhibitor of apoptosis proteins) in cancer cells[1]. These proteins help cancer cells survive and resist cell death. By blocking IAPs, Tolinapant may help promote cancer cell death and potentially slow down or stop tumor growth. Specifically, Tolinapant has been shown to cause the degradation of a protein called cIAP1 in blood cells, which is believed to be one of its mechanisms of action against cancer[2].

What Conditions Does Tolinapant Treat?

Tolinapant is being studied for the treatment of several types of advanced cancers and lymphomas that have not responded well to standard treatments or have come back after previous therapies. The main conditions being investigated include:

  • Peripheral T-cell lymphoma (PTCL): A group of rare and aggressive blood cancers that develop from T-cells[1][2]
  • Cutaneous T-cell lymphoma (CTCL): A type of lymphoma that primarily affects the skin[2]
  • Diffuse large B-cell lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma[2]
  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that affects the mouth, throat, or voice box[2]
  • Cervical carcinoma: Cancer of the cervix that has not responded to or has relapsed after standard therapy[2]

Additionally, researchers are exploring the potential of Tolinapant in treating other types of tumors that may be sensitive to its mechanism of action[2].

Clinical Trials and Research

Tolinapant is currently being studied in clinical trials to evaluate its safety, effectiveness, and optimal dosing. Two main clinical trials are ongoing:

  1. A Phase 1-2 study combining Tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL)[1].
  2. A Phase 1-2 study of Tolinapant alone in patients with various advanced solid tumors and lymphomas[2].

These trials aim to determine the best dose of Tolinapant, assess its safety profile, and evaluate its effectiveness in treating different types of cancers. Researchers are particularly interested in studying how well Tolinapant works in patients who have not responded to other treatments or whose cancer has come back after previous therapies.

Administration and Dosing

Tolinapant is administered orally in the form of capsules[1][2]. The exact dosing schedule may vary depending on the specific clinical trial and the patient’s condition. In some studies, Tolinapant is given once a day for 7 consecutive days, followed by 7 days off, in a repeating 28-day cycle[2]. However, researchers are also exploring other dosing regimens to determine the most effective and safe way to administer the drug.

Potential Side Effects

As Tolinapant is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are closely monitoring patients for any adverse reactions. Some potential side effects that are being evaluated include:

  • Changes in blood cell counts
  • Liver function abnormalities
  • Gastrointestinal symptoms
  • Fatigue
  • Cardiac effects (patients with certain heart conditions are excluded from the trials)[1][2]

It’s important to note that the safety profile of Tolinapant is still being established through ongoing clinical trials.

Conclusion

Tolinapant represents a promising new approach in the treatment of advanced cancers and lymphomas. By targeting IAP proteins, it may offer a new option for patients who have not responded well to other treatments. While the research is still ongoing, early results have shown encouraging signs of effectiveness, particularly in certain types of lymphomas. As clinical trials progress, more information will become available about Tolinapant’s safety, efficacy, and potential role in cancer treatment.

Aspect Details
Drug Name Tolinapant Lactate (ASTX660)
Administration Oral capsules
Cancer Types Studied PTCL, CTCL, DLBCL, Head and neck squamous cell carcinoma, Other solid tumors
Trial Phases Phase 1-2
Primary Objectives Assess safety, determine optimal dose, evaluate efficacy
Secondary Objectives Measure pharmacokinetics, evaluate response duration and progression-free survival
Key Eligibility Criteria Adults with advanced cancers, relapsed/refractory disease, adequate organ function
Main Exclusion Criteria Certain cardiac conditions, active infections, recent anticancer treatments

FAQ

  • What is Tolinapant Lactate? Tolinapant Lactate, also known as ASTX660, is a new drug being studied for its potential to treat various advanced cancers, including solid tumors and lymphomas. It works by targeting specific proteins involved in cancer cell survival.
  • What types of cancers are being studied in these clinical trials? The clinical trials are focusing on several types of advanced cancers, including peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), diffuse large B-cell lymphoma (DLBCL), head and neck squamous cell carcinoma, and other solid tumors that may be sensitive to Tolinapant Lactate.
  • How is Tolinapant Lactate administered in these trials? Tolinapant Lactate is given orally in the form of capsules. The dosing schedule may vary, but one trial used a regimen of daily dosing for 7 consecutive days every other week of each 28-day cycle.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety of Tolinapant Lactate, determine the best dose and schedule for treatment, evaluate how the drug works in the body (pharmacokinetics), and measure its effectiveness in treating various types of cancer.
  • Who can participate in these clinical trials? Eligible participants are generally adults (18 years or older) with advanced cancers that have not responded to standard treatments or have relapsed. Specific eligibility criteria may vary depending on the particular trial and cancer type being studied.

Ongoing Clinical Trials on Tolinapant Lactate

  • Study on the Safety and Effects of Tolinapant in Patients with Advanced Solid Tumors and Lymphomas

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Hungary Italy Poland Spain

Glossary

  • Peripheral T-cell lymphoma (PTCL): A group of rare and aggressive blood cancers that develop from mature T-cells, a type of white blood cell important for immune function.
  • Cutaneous T-cell lymphoma (CTCL): A type of cancer that begins in T-cells and primarily affects the skin, causing various types of skin lesions.
  • Diffuse large B-cell lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that affects B-cells, another type of white blood cell involved in immune response.
  • Head and neck squamous cell carcinoma: A type of cancer that begins in the flat cells lining the inside of the mouth, nose, throat, or voice box.
  • Relapsed/Refractory: Refers to cancer that has returned after treatment (relapsed) or does not respond to treatment (refractory).
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be appropriate for further testing in Phase 2 clinical trials based on safety and efficacy data from Phase 1 trials.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.

References

  1. http://clinicaltrials.eu/trial/study-of-tolinapant-with-decitabine-and-cedazuridine-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-tolinapant-in-patients-with-advanced-solid-tumors-and-lymphomas/